Welcome to our dedicated page for Solventum SEC filings (Ticker: SOLV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Solventum's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Solventum's regulatory disclosures and financial reporting.
Solventum Corp (SOLV) reported an equity award to its Chief Commercial Officer in a Form 4 insider transaction filing. The officer received 78,751 restricted stock units (RSUs) on November 17, 2025. Each RSU represents the right to receive one share of Solventum Class A common stock upon settlement.
The RSUs vest in three equal tranches, with one-third vesting on November 17, 2026, one-third on November 17, 2027, and the final third on November 17, 2028, assuming continued service through each vesting date. Following this grant, the filing shows 78,751 derivative securities beneficially owned on a direct basis, reflecting this new RSU award as part of the executive's long‑term incentive compensation.
Solventum Corp (SOLV) filed an initial ownership report for one of its officers. The reporting person serves as Chief Commercial Officer of Solventum Corp and submitted a Form 3 as an initial statement of beneficial ownership as of 11/10/2025. The filing states that no securities are beneficially owned by this officer at the time of the reported event, and that a power of attorney (Exhibit 24.1) authorizes the attorney-in-fact to sign on the officer’s behalf.
Independent Franchise Partners, LLP filed an amended Schedule 13G (Amendment No. 1) reporting beneficial ownership of 12,899,240 shares of Solventum Corporation common stock, representing 7.44% of the class as of 09/30/2025.
The filer reports 12,626,471 shares with sole voting power and 77,036 with shared voting power. It has 12,899,240 shares with sole dispositive power and 0 with shared dispositive power. The filing certifies the securities were acquired and are held in the ordinary course of business and not with the purpose or effect of changing or influencing control of the issuer.
Solventum Corporation (SOLV) reported Q3 2025 results highlighted by a completed divestiture and significant de-leveraging. The company sold its Purification and Filtration business to Thermo Fisher for approximately $4 billion cash, recording a pre-tax gain of approximately $1.5 billion (net of $86 million in transaction fees). Q3 diluted EPS was $7.22 on total net sales of $2,096 million.
Long-term debt declined to $5,137 million from $7,810 million at year-end, aided by cash tender offers retiring $1.9 billion of senior notes, which produced an $82 million loss on extinguishment (including instruments activity). Cash and equivalents rose to $1,642 million. Operating cash flow for the nine months was $274 million, reflecting the non-cash nature of the $1,518 million gain and working capital movements. The company recognized an unfavorable contract liability of $113 million tied to transition services and recorded a $64 million liability related to a potential payment of up to $75 million associated with the excluded Water Business.
Q3 gross profit was $1,135 million; SG&A was $780 million and R&D was $183 million. Shares outstanding were 173,439,525 as of September 30, 2025.
Solventum Corporation furnished an update on its business by reporting third‑quarter 2025 results and providing the related press release as Exhibit 99.1 under Item 2.02 of a Form 8‑K. The exhibit contains the detailed financial results and commentary. The filing notes the press release is furnished, not filed, under the Exchange Act.
Solventum Corporation appointed Heather Knight as Chief Commercial Officer, effective November 10, 2025. She will oversee global commercial and R&D operations across the MedSurg, Dental Solutions, and Health Information Systems segments, reporting directly to CEO Bryan Hanson.
In connection with the appointment, Chris Barry, Executive Vice President and Group President of MedSurg, will depart effective December 31, 2025. Upon executing and not revoking a general release of claims, he will receive severance benefits under the Solventum Executive Severance Plan, and his outstanding equity awards will be treated under applicable award agreements.
Knight brings 30+ years of MedTech leadership, most recently as COO at Baxter International, with prior roles at Medtronic, Covidien, Tyco Healthcare, and Kendall, and board service at Waters Corporation.
Solventum Corporation filed an 8-K describing updates to its cash tender offers for certain outstanding debt securities. The company reported results as of the early participation date and increased the size of these note tender offers.
Solventum also announced the pricing terms of the tender offers, each described in separate press releases dated September 8, 2025. The company emphasized that the tender offers are being made only under an Offer to Purchase dated August 22, 2025, as amended on September 8, 2025, and only where permitted by applicable law.
Solventum Corp (SOLV) director and Chief Executive Officer Bryan C. Hanson reported changes in his beneficial ownership on 09/01/2025. Hanson had 67,261 restricted stock units (RSUs) vest following conversion of previously granted 3M RSUs into Solventum RSUs under the Employee Matters Agreement; those vested RSUs were recorded at $0 acquisition price. The filing also shows a separate sale of 26,468 common shares at $73.09 each on the same date. After these reported transactions, the filing lists Hanson's direct beneficial ownership as 102,398 shares. The RSUs settle one-for-one into Class A common shares and vest in three equal annual tranches from the grant date; the derivative RSUs list an expiration/related date of 09/01/2033. The Form 4 was signed by an attorney-in-fact on 09/02/2025.
Solventum Corporation completed the sale of its purification and filtration business (excluding its drinking water filtration business) to Thermo Fisher Scientific Inc. under an Amended and Restated Transaction Agreement. Solventum received approximately $4.0 billion in cash at closing, subject to customary adjustments for cash, debt, transaction expenses and working capital. The terms also include a potential payment of up to $75 million from Solventum to Thermo Fisher, either upon a sale of the drinking water filtration business or after an agreed three‑year period. Solventum issued a press release describing the closing, and pro forma financial information giving effect to the transaction is incorporated by reference from a prior filing.
Solventum Corporation has launched cash tender offers to repurchase up to $1,750,000,000 of its outstanding senior notes. The company is offering to buy its 5.450% Senior Notes due 2027, 5.400% Senior Notes due 2029, 5.600% Senior Notes due 2034 and 5.450% Senior Notes due 2031 for a combined purchase price of up to $1,250,000,000, with the 2027 notes capped at $500,000,000. It is also offering to purchase its 6.000% Senior Notes due 2064 and 5.900% Senior Notes due 2054 for up to $500,000,000. The offers are described in an Offer to Purchase dated August 22, 2025 and are subject to stated terms and conditions, including a financing condition.